Fig. 2

TANs promote tumor progression through the CCL5-CCR5 axis. (A) The anti-CCL5 neutralizing antibody suppressed the migration and invasion of SUIT-2 and MIA PACA-2 cells treated with conditioned TANs (TAN’CM) medium, as assessed using transwell assays (n = 3 per group). (B) Migration and invasion of KPC-1 mouse pancreatic cancer cells treated with conditioned medium from neutrophils in mouse peripheral blood (PBN’CM) or those isolated from orthotopic pancreatic tumors (TAN’CM) with or without the anti-CCL5 antibody. (C) Representative microphotographs of migrating (top) and invading (bottom) KPC-1 cells. (D) Experimental schema demonstrating the orthotopic implantation of KPC-1 or KPC-2 cells into C57/B6 mice, n = 5. (E) Representative in situ images of tumors from KPC-1 cells and (F) quantified graphs of tumor weight in KPC-1 or KPC-2-transplanted mice after treatment. (G) Quantification for the immunohistochemistry of FOXP3⁺, Granzyme B⁺, and IFN-γ⁺ cells in orthotopically transplanted mice tumors. (H) Representative images for the immunohistochemistry of FOXP3⁺, Granzyme B⁺, and IFN γ⁺ cells in orthotopically transplanted mouse tumors. Arrows indicate positive staining. Scale bar, 100 μm. (I) Experimental schema showing the orthotopic implantation of KPC-2 cells into female C57/B6 mice and subsequent intraperitoneal injection with anti-Ly6G and maraviroc; n = 5. (J) Photographs of resected tumors and (K) quantified graphs of tumor weight in KPC-2-transplanted mice after treatment. *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant